International Biotechnology Trust Announces Strategic Partnership with Schroders Capital

International Biotechnology Trust PLC (LON: IBT) has announced a strategic partnership with Schroders Capital to expand its investments in unquoted biotechnology companies.

The move aims to provide shareholders with access to innovative, early-stage ventures, diversifying the portfolio by manager, vintage, and geography.

IBT will make an initial commitment of £10 million, roughly 4% of its current portfolio value, to the Partnership. This capital will be deployed over time into funds specializing in unquoted biotechnology. This commitment falls inside the range of 5-15% of portfolio value, to unquoted companies.

Schroders Capital brings over 25 years of experience in healthcare and biotechnology, having committed over $4.3 billion across nearly 700 investments globally. Their expertise and established relationships with leading managers across North America, Europe, and Asia are expected to provide IBT with access to differentiated investment opportunities.

The Partnership agreement stipulates a management fee of 0.9% per annum based on the asset value of IBT's investment in the Partnership, plus an annual administration fee of £25,000. Aggregate fees are capped at 0.25% of IBT's net asset value, ensuring cost efficiency.

IBT's existing unquoted exposures, representing approximately 8.4% of the portfolio, are primarily held in two funds managed by SV Health Partners. These holdings, which have demonstrated strong performance, will remain separate from the new Partnership with Schroders Capital. No changes are anticipated for these existing holdings.